Pathora Bio — From Tissue <span style="color:#ffffff !important;">to</span> Insight

Why Pathora Bio

Built for accountable tissue biomarker execution

Pathora Bio brings histology, multiplex assay development, digital pathology, biomarker analytics, and scientific interpretation into one coordinated workflow.

Single Workflow Ownership

One coordinated process from specimen intake through reporting, reducing fragmented handoffs and lost accountability.

QC-Driven Execution

Tissue quality, assay readiness, imaging quality, and analysis outputs are reviewed as connected parts of the same workflow.

Scalable Platform Strategy

Platform-agnostic planning supports low-plex, high-plex, spatial, and digital pathology workflows based on the project need.

Analysis-Ready Data

Structured image and biomarker outputs are designed for downstream review, interpretation, and translational decision-making.

Traceable Deliverables

Organized reporting, QC summaries, image files, annotations, and data tables support reproducible client-facing delivery.

Florida to Worldwide

Built from Florida with a service model designed for broader translational research and clinical trial support opportunities.

Who We Serve

Built for modern biomarker programs

Pathora Bio is designed for teams that need reliable tissue biomarker data, accountable execution, and CRO-grade delivery across discovery, translational research, and clinical development.

Pharma

Integrated pathology workflows supporting translational oncology, biomarker strategy, and tissue-to-data programs.

Biotech

Flexible CRO-grade histology, multiplex imaging, spatial-ready QC, and digital pathology analytics.

Clinical Trial Teams

Specimen handling, pathology review, assay support, quantitative analysis, and structured reporting pipelines.

Academic Collaborators

Execution-focused workflows that bridge translational science, pathology review, imaging, and data delivery.

The Business Case

A pathology infrastructure business built around execution

Pathora Bio translates advanced tissue science into a clear business problem: fragmented academic and vendor workflows delay tissue biomarker programs for pharma, biotech, and clinical research teams. We centralize specimen intake, pathology review, histology, multiplex imaging, digital pathology, analytics, QC, and delivery into one accountable CRO-grade workflow.

Operational Pain

Clients lose time when tissue retrieval, pathology review, sectioning, staining, imaging, and analysis are split across disconnected groups.

Premium Service Model

Pathora Bio is positioned as a high-end translational pathology CRO, not a commodity histology lab.

Miami-Based, Global Reach

Headquartered in South Florida with a scalable model for national and international pharma, biotech, and clinical research clients.

Investor-Friendly Story

The value is simple: faster execution, better tissue biomarker data, accountable delivery, and CRO-grade quality systems.

Core Services

End-to-end tissue
biomarker capability

Eight focused, high-margin services — designed for pharma-grade execution with integrated QC, LIMS tracking, and chain-of-custody from day one.

FFPE Histology & Tissue QC

FFPE sectioning, H&E, tissue QC, and slide preparation supported by ASCP-certified histotechnicians, standardized accessioning, and morphology-aware review.

🔬

IHC, FISH & RNAscope

Automated and semi-automated tissue assay workflows including IHC, FISH, and RNAscope/ISH approaches using ACD-Leica-aligned methods where applicable.

📶

Multiplex Assay Development

Platform-agnostic multiplexing strategy for low-plex and high-plex tissue studies, including antibody testing, panel development, validation, QC, and scalable throughput.

Clinical Trial Support

RUO-to-clinical trial support with QA-driven workflows, CLIA/CAP roadmap awareness, controlled documentation, clinical team coordination, and structured deliverables.

🖥️

AI & Digital Pathology

Quantitative pathology using major commercial platforms such as Visiopharm OncoPix, inForm/PhenoptrReports, AtoMx, Loupe Browser, Xenium Explorer, and custom Python/R pipelines.

🧠

Scientific & Data Interpretation

Integrated review by computationally trained in-house data scientists and board-certified molecular pathology advisors to connect tissue biology, imaging, and biomarker interpretation.

One Integrated Workflow

Accelerated specimen-to-insight workflows

Faster, accountable execution under one system — no fragmented handoffs, no lost ownership, no delays.

Specimen Intake

Blocks · Slides
TMAs · WSI

Histology & QC

FFPE · H&E
Sectioning · Tissue Stamping

Multiplex Assay

IHC · IF
Panel Optimization · Probe hybridization / Seq. / In situ seq.

Digital Imaging

WSI Scanning
Spatial Platforms

AI Analysis

AI-Assisted
Quantification

Biomarker Report

Structured
Research & Clinical Grade

Standards & Compliance

Accreditation & Quality

Pathora Bio operates under the highest quality standards in clinical and research laboratory science, with accreditations that ensure the reliability and reproducibility of every result.

CLIA

CLIA Readiness Framework Designed around clinical laboratory operational standards, documentation structure, QC oversight, specimen traceability, and scalable compliance workflows.

CAP

CAP-Aligned Quality Systems SOP-driven operational design supporting reproducibility, audit readiness, workflow standardization, and CRO-grade execution practices.

Quality & Compliance Infrastructure Structured around accountability, specimen tracking, reporting consistency, operational transparency, and high-end translational pathology workflows.

CLIA

CLIA Certified

CAP

CAP Accredited

ISO

ISO-Aligned Processes

GLP

GLP Principles

Investment Opportunity

Investor Opportunities

Pathora Bio is being built around a practical bottleneck in cancer and disease research: tissue biomarker programs are often slowed by fragmented handoffs, unclear workflow ownership, and inconsistent outputs. The company integrates pathology, imaging, AI-assisted digital analysis, and biomarker reporting into one accountable specimen-to-insight workflow for biotech, pharma, and translational research teams.

$8B+

CRO histopathology & biomarker services market

22%

Annual growth in multiplex IF & spatial biology adoption

$2.5M

Seed funding target for operational buildout

Global

Pharma, biotech & translational research reach

Florida Hub USA Nationwide Europe Asia-Pacific Worldwide

Remaining Leadership & Advisory Buildout

Chief Executive Officer

Planned business leader to support fundraising, commercial strategy, partnerships, and company scale-up.

MD / PhD Pathologist

Advisor/medical director track to support pathology review, biomarker interpretation, clinical alignment, and scientific credibility.

Operations & QA Lead

Operations and QA leadership for lab workflow, SOPs, quality systems, CAP/CLIA readiness, and project execution.

Request Investor Deck

From
Tissue
to Insight

Integrated tissue biomarker intelligence

Built for accountable tissue biomarker execution